智通财经APP获悉，长风药业(02652)午前涨近3%，截至发稿，涨2.74%，报29.2港元，成交额536.45万港元。
消息面上，据长风药业官微消息，近日，长风药业自研支气管活瓣肺减容装置成功完成首例受试者入组(FPI)，本临床验证阶段由此正式拉开帷幕，旨在为肺气肿等慢阻肺(COPD)相关人群拓展一条微创介入治疗路径。首例入组手术的顺利完成，标志着此项创新微创介入器械正式进入临床验证阶段。
据介绍，肺气肿患者常见动态过度充气与活动受限，现有疗法在实现长效管理与显著改善生活质量方面，存在大量未满足的临床需求。本次人体实验装置依托支气管镜下的分支级别气流调控与目标肺区减容策略，力求在降低残气量(RV)的同时，改善肺功能与运动耐量，并在个体化评估基础上提高可重复性与术后管理可控性。
本研究将按方案推进持续入组、围手术期安全监测与影像学/肺功能多维评估，主要指标覆盖装置与操作相关安全性、技术成功率等，并观察FEV1、RV、6MWD及SGRQ等关键临床结局的变化趋势;研究数据将形成可审计的证据链，用于后续的注册策略与商业化决策。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.